197 related articles for article (PubMed ID: 26232337)
1. Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.
Depreeuw J; Hermans E; Schrauwen S; Annibali D; Coenegrachts L; Thomas D; Luyckx M; Gutierrez-Roelens I; Debruyne D; Konings K; Moerman P; Vergote I; Lambrechts D; Amant F
Gynecol Oncol; 2015 Oct; 139(1):118-26. PubMed ID: 26232337
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
3. Establishment of Patient-Derived Tumor Xenograft Models of High-Risk Endometrial Cancer.
Zhu M; Jia N; Nie Y; Chen J; Jiang Y; Lv T; Li Y; Yao L; Feng W
Int J Gynecol Cancer; 2018 Nov; 28(9):1812-1820. PubMed ID: 30358704
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumor.
Schrauwen S; Coenegrachts L; Depreeuw J; Luyten C; Verbist G; Debruyne D; Vergote I; Lambrechts D; Amant F
Int J Gynecol Cancer; 2015 Mar; 25(3):363-71. PubMed ID: 25695543
[TBL] [Abstract][Full Text] [Related]
6. The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo.
Schrauwen S; Coenegrachts L; Cattaneo A; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Aug; 138(2):378-82. PubMed ID: 26050920
[TBL] [Abstract][Full Text] [Related]
7. Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer.
Bissig-Choisat B; Kettlun-Leyton C; Legras XD; Zorman B; Barzi M; Chen LL; Amin MD; Huang YH; Pautler RG; Hampton OA; Prakash MM; Yang D; Borowiak M; Muzny D; Doddapaneni HV; Hu J; Shi Y; Gaber MW; Hicks MJ; Thompson PA; Lu Y; Mills GB; Finegold M; Goss JA; Parsons DW; Vasudevan SA; Sumazin P; López-Terrada D; Bissig KD
J Hepatol; 2016 Aug; 65(2):325-33. PubMed ID: 27117591
[TBL] [Abstract][Full Text] [Related]
8. PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
Marchiò C; De Filippo MR; Ng CK; Piscuoglio S; Soslow RA; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2015 May; 137(2):321-8. PubMed ID: 25701704
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.
Bonazzi VF; Kondrashova O; Smith D; Nones K; Sengal AT; Ju R; Packer LM; Koufariotis LT; Kazakoff SH; Davidson AL; Ramarao-Milne P; Lakis V; Newell F; Rogers R; Davies C; Nicklin J; Garrett A; Chetty N; Perrin L; Pearson JV; Patch AM; Waddell N; Pollock PM
Genome Med; 2022 Jan; 14(1):3. PubMed ID: 35012638
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
Merk J; Rolff J; Becker M; Leschber G; Fichtner I
Eur J Cardiothorac Surg; 2009 Sep; 36(3):454-9. PubMed ID: 19502076
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models.
Cuppens T; Depreeuw J; Annibali D; Thomas D; Hermans E; Gommé E; Trinh XB; Debruyne D; Moerman P; Lambrechts D; Amant F
Gynecol Oncol; 2017 Sep; 146(3):538-545. PubMed ID: 28625393
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors.
Cho YB; Hong HK; Choi YL; Oh E; Joo KM; Jin J; Nam DH; Ko YH; Lee WY
J Surg Res; 2014 Apr; 187(2):502-9. PubMed ID: 24332554
[TBL] [Abstract][Full Text] [Related]
14. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Xenograft Models for Endometrial Cancer Research.
Moiola CP; Lopez-Gil C; Cabrera S; Garcia A; Van Nyen T; Annibali D; Fonnes T; Vidal A; Villanueva A; Matias-Guiu X; Krakstad C; Amant F; Gil-Moreno A; Colas E
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126113
[TBL] [Abstract][Full Text] [Related]
16. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Matulonis U; Vergote I; Backes F; Martin LP; McMeekin S; Birrer M; Campana F; Xu Y; Egile C; Ghamande S
Gynecol Oncol; 2015 Feb; 136(2):246-53. PubMed ID: 25528496
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
Prendergast EN; Holman LL; Liu AY; Lai TS; Campos MP; Fahey JN; Wang X; Abdelaal N; Rao JY; Elvin JA; Moore KM; Konecny GE; Cohen JG
Gynecol Oncol; 2019 Sep; 154(3):461-466. PubMed ID: 31257009
[TBL] [Abstract][Full Text] [Related]
19. New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?
Rodriguez-Freixinos V; Karakasis K; Oza AM
Curr Oncol Rep; 2016 Apr; 18(4):23. PubMed ID: 26922329
[TBL] [Abstract][Full Text] [Related]
20. Endometrial carcinoma: molecular alterations involved in tumor development and progression.
Yeramian A; Moreno-Bueno G; Dolcet X; Catasus L; Abal M; Colas E; Reventos J; Palacios J; Prat J; Matias-Guiu X
Oncogene; 2013 Jan; 32(4):403-13. PubMed ID: 22430211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
